CLNN

CLNN

Clene Inc.

Clene Inc. develops novel clean-surfaced nanotechnology therapeutics, focusing on treating neurodegenerative diseases like ALS and Parkinson's. It also produces antimicrobial gels and dietary supplements containing zinc and gold for health support and wound healing.

โš’๏ธ Consumer Defensive NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$23today

Score Overview

1 Year
Score
Net Growth33.57%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-41.52%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.1
Net Growth-35.77%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-2.91%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth-35.77%
Net Trend60%
Net Income Consistency
Rev Growth-2.91%
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Clene Inc. fundamental performance

Between 2020 and 2025, revenue declined from $ 206K to $ 200K and net income went from -$ 19M to -$ 26M. Revenue increased in 2 of those 5 years; net income in 3.

Clene Inc. currently holds a 5-year HDB Score of 4.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.07โ€”
1 Year2025-08-12
$ 3.7010.00%
5 Years2021-08-12
$ 180.80-97.75%
All Time2020-12-31
$ 180.20-97.74%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 200K-$ 26M$ 5M
2024$ 342K-$ 39M$ 12M
2023$ 654K-$ 49M$ 35M
2022$ 473K-$ 29M$ 23M
2021$ 723K-$ 9M$ 50M
IPO2020$ 206K-$ 19M$ 59M

Explore beyond CLNN

You're looking at Clene Inc.. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies